MLTX
MoonLake Immunotherapeutics
10.80$
+2.3%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
MoonLake Immunotherapeutics (MLTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -56 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.3 | -0.1 | -26 | -2.0 | -7.5 | -14 | -21 | -9.4 | -12 | -9.0 | -12 | -9.3 | -12 | -15 | -28 | -25 | -48 | -38 | -55 | -45 | -59 | -66 | -56 | -225 | |
| – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.3 | 0.4 | 1.3 | 0.4 | 0.7 | 0.7 | 0.8 | 0.8 | 0.9 | 3.2 | |
| – | – | 1.3 | 1.9 | -1.9 | 2.0 | 2.5 | 2.6 | 2.6 | 2.6 | 1.5 | 1.4 | 1.6 | 1.7 | 1.8 | 1.8 | 1.9 | 2.3 | 3.3 | 3.7 | 3.6 | 13 | 2.5 | 23 | |
| – | 0.0 | 2.1 | 12 | -2.2 | 0.0 | 7.2 | 13 | 2.7 | 2.6 | 1.5 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 0.0 | 1.2 | 2.3 | 1.0 | -0.4 | -5.9 | 2.8 | 2.1 | 0.6 | -1.3 | 1.0 | -6.5 | -2.8 | -5.3 | 8.3 | -3.9 | -0.4 | -1.2 | 21 | -0.4 | -11 | 2.8 | 13 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.2 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -115 | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -42 | 9.9 | 20 | 13 | -174 | 117 | -29 | -88 | 58 | -147 | 56 | 88 | 88 | -30 | 0.1 | 0.3 | 59 | |
| – | – | – | – | 0.0 | – | – | – | -0.1 | 0.0 | 451 | 0.0 | – | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | |
| – | -0.1 | 15 | 18 | 18 | 0.2 | -15 | – | – | – | – | – | – | – | – | – | – | 73 | 0.0 | 0.0 | 0.0 | 24 | 0.0 | 24 | |
| 117 | -0.1 | 28 | 0.5 | 15 | 15 | 105 | 120 | 0.0 | 451 | 451 | 0.0 | 28 | 51 | 0.0 | 0.2 | 0.2 | 73 | 0.0 | 0.5 | 72 | 31 | 235 | 338 | |
| 1.3 | -0.2 | -0.1 | -1.5 | 7.0 | 0.8 | 84 | -52 | -1.7 | 11 | 452 | -184 | 133 | 7.3 | -116 | 33 | -195 | 91 | 35 | 44 | -16 | -36 | 179 | 171 | |
| -0.3 | -0.1 | -26 | -2.0 | -7.5 | -14 | -21 | -9.4 | -12 | -9.0 | -12 | -9.3 | -13 | -15 | -28 | -25 | -49 | -38 | -55 | -45 | -59 | -66 | -56 | -225 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.